Related Experiment Video
Updated: Jun 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Therapies for diabetic dyslipidaemia
D S H Bell1, F Al Badarin, J H O'Keefe
1Department of Endocrinology, University of Alabama, Birmingham, AL 35205, USA. dshbell@yahoo.com
Managing diabetic dyslipidaemia is crucial for reducing cardiac risk in diabetes patients. Effective management involves controlling blood glucose and lipid levels, often requiring combination therapies and lifestyle changes.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Disorders
Background:
- Diabetic dyslipidaemia presents a significant cardiovascular risk in diabetic patients.
- It is characterized by high triglycerides, low high-density lipoprotein (HDL), and small, dense low-density lipoprotein (LDL) particles.
- Correcting non-HDL cholesterol is a primary therapeutic objective.
Purpose of the Study:
- To outline the importance of managing diabetic dyslipidaemia for cardiovascular risk reduction.
- To discuss therapeutic strategies for improving lipid profiles in diabetic patients.
- To highlight the role of glycaemic control and specific medications like pioglitazone.
Main Methods:
- Review of current therapeutic recommendations for diabetic dyslipidaemia.
- Emphasis on lifestyle modifications and pharmacological interventions.
- Discussion of combination therapies including statins, nicotinic acid, omega-3 fats, and bile acid sequestrants.
Main Results:
- Pioglitazone shows efficacy in improving diabetic dyslipidaemia, inflammation, and hyperglycaemia.
- Statins are recommended for most type 2 diabetes patients to lower LDL cholesterol to <100 mg/dl.
- Combination therapies are often necessary to achieve optimal lipid levels, targeting triglycerides and HDL-C.
Conclusions:
- Comprehensive management of diabetic dyslipidaemia is essential for mitigating cardiac events.
- Achieving target lipid levels typically requires a multi-faceted approach combining lifestyle changes and pharmacotherapy.
- Further research may be needed to clarify the role of fibrates in reducing adverse cardiovascular events in this population.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Diabetic Retinopathy